Table 2.
Cytotoxic and antiviral activities of formulations against tick-borne encephalitis virus (TBEV) and herpes simplex virus type 1 (HSV-1).
| Formulation | TBEV | HSV-1 | ||||
|---|---|---|---|---|---|---|
| CC50 (µg/mL) | IC50 (µg/mL) | SI | CC50 (µg/mL) | IC50 (µg/mL) | SI | |
| Ech + Asc + Toc (5:5:1) | 57.9 ± 2.3 * | 12.6 ± 1.5 ** | 4.8 ± 0.5 ** | 66.7 ± 3.2 * | 11.2 ± 1.2 ** | 6.0 ± 0.6 ** |
| Ech | 54.4 ± 1.8 * | 21.8 ± 2.6 * | 2.5 ± 0.2 * | 60.5 ± 3.1 * | 18.8 ± 2.1 * | 3.2 ± 0.3 * |
| Asc + Toc (5:1) | 521.7 ± 5.3 | 1304 ± 145 | 0.4 ± 0.1 | 530.9 ± 9.4 | 885 ± 97 | 0.6 ± 0.1 |
| Ribavirin | 2010 ± 180 | 30.5 ± 4.6 | 66.0 ± 5.4 | |||
| Acyclovir | 1470 ± 160 | 10.8 ± 1.2 | 133.6 ± 12.0 | |||
CC50-50% cytotoxic concentration of a formulation, IC50-50% virus-inhibiting concentration of a formulation, SI: selective index of the formulation. * Statistically significant differences between Asc + Toc and other formulation (p ≤ 0.05), ** statistically significant differences between antioxidant composition and Ech (p ≤ 0.05).